FDA Approves Animas Vibe and CGM for Children

Animas Vibe

The U.S. FDA has approved Animas Vibe Insulin Pump and Continuous Glucose Monitoring (CGM) System for management of diabetes in children and adolescents, ages 2 to 17. The Animas Vibe System was the first integrated system with Dexcom G4 PLATINUM … Read more

FDA Revises Labels of SGLT2 Inhibitors

FDA large logo

A U.S. FDA safety review has resulted in adding warnings to the labels of a specific class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors (such as Invokana, Farxiga and Jardiance) about the risks of too much acid in the blood and of serious urinary tract infections. Both conditions can result in hospitalization. Read more

Medtronic Discontinues The Sof-sensor CGM Sensor


Medtronic has announced that it will no longer sell its CGM Sof-sensor as of Dec. 1, 2015. Medtronic is offering no out of pocket cost conversion programs to their latest insulin pump and CGM technology, the MiniMed 530G with Enlite. Read more

FDA Approval for Tresiba and Ryzodeg, Long Lasting Insulin Drugs

Novo_Nordisk large

More than two years after dealing Novo Nordisk a surprising setback, the U.S. Food and Drug Administration has approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to improve blood sugar control in adults with diabetes mellitus. … Read more

Half of US adults have diabetes or pre-diabetes, study says

Half of US adults have diabetes or pre-diabetes

New research suggests that half of all U.S. adults have diabetes or pre-diabetes.

The study of government health surveys echoes previous research and shows numbers increased substantially between 1988 and 2012 although they mostly leveled off after 2008. Overall, 12 percent to 14 percent of adults had diagnosed diabetes in 2012, the latest data available. Most of that is Type 2 diabetes, the kind linked with obesity and inactivity. Read more

Subscribe to our Newsletter

Hide me